A new study has found that a combination of two drugs could enhance the immune system to treat one of the most common types of cancer in the world, bowel cancer. Also known as colorectal cancer, despite its widespread presence, the treatment options for this condition are limited. What the study specifically found was that this procedure could shrink the tumours caused by this condition by around 60%.
What Are The Drugs Involved
The trial involved the use of two immunotherapy drugs, botancilimab and balstilumab. It is a monoclonal antibody that works to stimulate the body's immune system to attack cancer. The study is a rather significant find, as it’s the first time that a consistent and durable response to immunotherapy has been reported in patients with solid MSS mCRC tumours.
The study was divided into several phases for more than 6 months. In the US trial, around around 101 patients with microsatile stable metastatic colorectal (MSS-mCRC) tumours showed a decrease . Around 61% of the patients experienced tumour shrinkage or stabilization after combined treatment with votancilumab and balstilumab. When it comes to downsides, diarrhea and fatigue were found to be the most common side effects or side effects of this drug.
These results are interesting and open to exploration. To date, immunotherapy has not been effective in patients with CNS-mCRC tumors. This study demonstrates the potential of the combination of botenlimab and balstilimab in the treatment of CNS mCRC, providing new hope for people diagnosed with colon cancer.
What Could This Mean For Bowel Cancer Treatment In The Future
The study is currently in the final stages of clinical trials, and the US Food and Drug Administration (FDA) hopes to quickly gain approval for its use because of the importance of this area that affects many people. The efficiency shown demonstrates the potential of botansilimab to contribute to broad antitumor immunity.
All in all, the combination of botensilimab and balstilimab represents a promising new direction in the treatment of colorectal cancer. This breakthrough could improve conditions for many patients worldwide and lights a new hope in the fight against this common disease. The results of this study show the effectiveness of immunotherapy in this field and how its potential to transform cancer treatment can only grow in the years to come.
Credits: Canva
Measles Outbreak In UK: A measles outbreak has been confirmed in London's north east area, noted the BMJ. As per the medical journal, the outbreak is among the unvaccinated children. The medical journal also noted that there have been 96 laboratory confirmed cases of measles in England between January 1 to February 9, 2026 and more than a third, which is 34 cases are from Enfield. BMJ also noted that Enfield is also the area with lowest vaccination rates.
As per the data by the UK Health Security Agency or the UKHSA, only 64.3% of 5 year-olds Enfield received both doses of the measles, mumps, and rubella or the MMR vaccine in 2024 and 2025. The majority (74 of 96, 77%) of measles cases confirmed in the UK so far this year were in children aged 10 and under. Some 64% of cases have been in London, 26% in the West Midlands, and 4% in the East Midlands.
Read: Unique Symptoms Of Measles In 2026 And How Long Does The Infection Last?
Last month, the World Health Organization revoked the United Kingdom’s measles elimination status after the virus was found to be circulating continuously for over a year.
In 2025, a child in Liverpool died after contracting measles, prompting renewed pressure on the NHS and government to address its return. England recorded 959 laboratory-confirmed cases that year. Although lower than the 2,911 cases in 2024, it still marked the highest annual total since 2012.
Vaccine uptake has steadily declined over the past 12 years. Only 84.4% of children in the UK receive both doses of the MMR vaccine by age five, far below the 95% coverage needed for herd immunity.
In late 2023, measles outbreaks were reported in the UK, which led to a surge in cases in 2024. Vaccination uptake at the end of 2024 was 92% for the first dose, however, for the second dose, it was below 82%.
Dr Vanessa Saliba, consultant epidemiologist at UKHSA said, "Infections can return quickly when childhood vaccine uptake falls - measles elimination is only possible if all eligible children receive two MMRV doses before school. The NHS is making vaccination easier, including offering the second MMRV dose earlier at a new 18-month appointment to boost uptake and support elimination goals."
Read: UK Loses Measles Elimination Status: Why Is This Disease Making A Comeback?
She also noted that children and adults must get vaccinated as NHS also offers catch-up jabs.
Dr Baharat Pankhania, from the University of Exeter, as reported by the BBC said, "Measles is an infection that can be prevented by vaccine - and it's extremely concerning that in the UK we now have pockets of low or no vaccine uptake. We urgently need to remedy this situation." Pankhania also noted that there is a need to make the access to GPs easier, and for an effort that could immunize babies in their homes and counter wrong information around vaccine safety.
The Union Minister of Health and Family Welfare, JP Nadda, today launched two key national initiatives -- the Strategy for Artificial Intelligence in Healthcare for India (SAHI) and the Benchmarking Open Data Platform for Health AI (BODH) to boost the role of AI in the country's healthcare ecosystem.
The initiatives, launched at the India AI Summit at Bharat Mandapam, in the national capital, are aimed at promoting safe, transparent, and accountable AI in healthcare. It will also help strengthen the digital health ecosystem for equitable healthcare access.
SAHI is a national guidance framework to enable the safe, ethical, evidence-based, and inclusive adoption of AI across India’s healthcare system.
It aims to provide strategic direction on governance, data stewardship, validation, deployment, and monitoring of AI solutions, while supporting States and institutions in responsible adoption aligned with public health priorities.
"SAHI is not merely a technology strategy but a governance framework, policy compass, and national roadmap for the responsible use of AI in healthcare,” said Nadda.
He stated that SAHI will guide India in leveraging AI in a manner that is ethical, transparent, accountable, and people-centric. Nadda also emphasized that SAHI provides a structured framework for collaboration, ensuring that innovation flourishes while public interest remains paramount.
The second initiative, BODH, was developed by the Indian Institute of Technology Kanpur in collaboration with the National Health Authority. It is a privacy-preserving benchmarking platform that enables rigorous evaluation of AI models using diverse, real-world health data without sharing underlying datasets.
As a digital public good under the Ayushman Bharat Digital Mission, it is designed to strengthen trust, transparency, and quality assurance in Health AI deployment.
"The collaboration between Government and academia has led to the development of BODH -- the Benchmarking Open Data Platform for Health AI -- which provides a structured mechanism for testing and validating AI solutions before deployment at scale,” said Nadda.
Nadda reiterated that AI solutions must be rigorously evaluated for performance, reliability, and real-world readiness. Together, SAHI and BODH represent India’s commitment to building a trustworthy, inclusive, and globally competitive health AI ecosystem grounded in innovation, responsibility, and public trust.
Earlier, delivering the keynote address at a session themed “Innovation to Impact: AI as a Public Health Game-Changer”, at the Summit, Anupriya Patel, Union Minister of State for Health and Family Welfare, highlighted AI as an "All-Inclusive Intelligence".
She also emphasized AI's potential in addressing "health inequities across the country".
Patel called technology -- particularly AI "an indispensable enabler" in India's race towards the vision of a Viksit Bharat by 2047.
She highlighted the potential role of AI on India’s vast and diverse population, the rural–urban divide, and the dual burden of communicable and non-communicable diseases, which present unique challenges.
She also noted that AI has been integrated across the entire continuum of healthcare -- from disease surveillance and prevention to diagnosis and treatment.
Credit: Canva
While the national capital is seeing a significant rise in H3N2 Influenza A cases, experts explained that it's not just the common cold and people must not try to self-medicate.
Speaking to Health And Me, multiple experts stressed the need to treat the virus properly, as its symptoms can last longer and potentially lead to pneumonia.
H3N2 is a subtype of the Influenza A virus that causes seasonal flu. The symptoms are often stronger and more persistent, with many patients reporting prolonged fatigue, cough, breathing difficulty, and slower recovery.
It is highly contagious, spreading via respiratory droplets (coughing/sneezing) and contaminated surfaces. The symptoms usually last 5–7 days, with treatment focusing on rest and symptom management.
Dr. Mohit Saran, Consultant - Internal Medicine and Diabetologist, Manipal Hospital, Gurugram, told this publication: “H3N2 is not just a common cold. While symptoms may not appear instantly, they can lead to high fever, constant cough, body pain, and breathing issues. In some people, this can also increase the risk of pneumonia or the need for hospitalization if not managed early.”
The experts attributed the surge in the disease to factors such as changing weather, fluctuating temperatures and reduced immunity.
Children, youngsters, senior citizens, pregnant women and people with low immunity or with conditions such as asthma, diabetes, or heart problems are more vulnerable to H3N2. Health care professionals and people who are exposed to crowded places may also be affected by this disease.
Dr. Atul Gogia, Head of Infectious Diseases, Sir Ganga Ram Hospital, told Health and Me that the H3N2 virus "predominantly affects elderly people and those who have comorbid illnesses".
"We need to be especially careful because this illness predominantly affects individuals with comorbid conditions, the elderly, and those who are more vulnerable to developing complications that may require hospitalization,” he said.
Symptoms of H3N2 infection can last for two to three weeks, with a lingering dry cough and fatigue being common.
The virus often affects the lower respiratory tract, leading to more intense coughing and breathing discomfort. Young children, older adults, and individuals with chronic health conditions are at higher risk of complications.
"H3N2 is considered more infectious because of its ability to mutate quickly and adapt to the human host. This high mutation rate allows the virus to evade the immune system more effectively and can lead to more severe outbreaks. It spreads easily through respiratory droplets, direct contact, and contaminated surfaces,” explained Dr. Manisha Arora, Director - Internal Medicine at the CK Birla Hospital(R), Delhi told HealthandMe
"Frequent changes in its surface proteins, a process known as antigenic drift, make it harder for the body to recognize and fight the virus, which can result in more hospitalizations and, in severe cases, increased mortality,”
H3N2 can be prevented through regular handwashing, wearing masks in crowded places, avoiding close contact with people who are sick, and avoiding self-medicating. Flu vaccination, timely medical consultation for long-term fever, and adequate rest help reduce the risk and further spread of the condition.
The experts recommended that all adults above 18 consider annual flu vaccination ideally in August or September, unless they are currently experiencing flu-like symptoms.
Maintaining good hygiene, eating nutrient-rich foods, staying hydrated, and following healthy habits can help boost immunity.
© 2024 Bennett, Coleman & Company Limited